163 related articles for article (PubMed ID: 10048472)
1. Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer.
Laudanski J; Burzykowski T; Niklinska W; Chyczewski K; Furman M; Niklinski J
Lung Cancer; 1998 Dec; 22(3):191-200. PubMed ID: 10048472
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of p53 and bcl-2 abnormalities in operable nonsmall cell lung cancer.
Laudanski J; Niklinska W; Burzykowski T; Chyczewski L; Niklinski J
Eur Respir J; 2001 Apr; 17(4):660-6. PubMed ID: 11401061
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy.
Blanchard P; Quero L; Pacault V; Schlageter MH; Baruch-Hennequin V; Hennequin C
BMC Cancer; 2012 Mar; 12():119. PubMed ID: 22448886
[TBL] [Abstract][Full Text] [Related]
4. Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma.
Iizasa T; Fujisawa T; Saitoh Y; Hiroshima K; Ohwada H
Cancer Immunol Immunother; 1998 Aug; 46(6):345-9. PubMed ID: 9756419
[TBL] [Abstract][Full Text] [Related]
5. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma.
Bourhis J; Lubin R; Roche B; Koscielny S; Bosq J; Dubois I; Talbot M; Marandas P; Schwaab G; Wibault P; Luboinski B; Eschwege F; Soussi T
J Natl Cancer Inst; 1996 Sep; 88(17):1228-33. PubMed ID: 8780633
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of serum p53 antibodies in squamous cell carcinoma of the lung.
Komiya T; Hirashima T; Takada M; Masuda N; Yasumitsu T; Nakagawa K; Hosono Y; Kikui M; Tsuji S; Fukuoka M; Kawase I
Anticancer Res; 1997; 17(5B):3721-4. PubMed ID: 9427768
[TBL] [Abstract][Full Text] [Related]
7. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
[TBL] [Abstract][Full Text] [Related]
8. Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma.
Shimada H; Shiratori T; Takeda A; Matsushita K; Okazumi S; Akutsu Y; Matsubara H; Nomura F; Ochiai T
World J Surg; 2009 Feb; 33(2):272-7. PubMed ID: 19052812
[TBL] [Abstract][Full Text] [Related]
9. The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival.
Bergqvist M; Brattström D; Larsson A; Hesselius P; Brodin O; Wagenius G
BMC Cancer; 2004 Sep; 4():66. PubMed ID: 15367333
[TBL] [Abstract][Full Text] [Related]
10. Serum anti-p53 autoantibodies in pleural malignant mesothelioma, lung cancer and non-neoplastic lung diseases.
Neri M; Betta P; Marroni P; Filiberti R; Cafferata M; Mereu C; Ivaldi G; Montanaro F; Puntoni R; Paganuzzi M
Lung Cancer; 2003 Feb; 39(2):165-72. PubMed ID: 12581569
[TBL] [Abstract][Full Text] [Related]
11. Measurement and evaluation of serum anti-p53 antibody levels in patients with lung cancer at its initial presentation: a prospective study.
Segawa Y; Kageyama M; Suzuki S; Jinno K; Takigawa N; Fujimoto N; Hotta K; Eguchi K
Br J Cancer; 1998 Sep; 78(5):667-72. PubMed ID: 9744508
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of serum p53 antibodies in lung cancer.
Mattioni M; Soddu S; Prodosmo A; Visca P; Conti S; Alessandrini G; Facciolo F; Strigari L
BMC Cancer; 2015 Mar; 15():148. PubMed ID: 25884692
[TBL] [Abstract][Full Text] [Related]
13. Serum p53 antibodies as a prognostic indicator in oral squamous cell carcinoma.
Yamazaki Y; Chiba I; Ishikawa M; Satoh C; Notani K; Ohiro Y; Totsuka Y; Mizuno S; Kitagawa Y
Odontology; 2008 Jul; 96(1):32-7. PubMed ID: 18661202
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of high serum p53 antibody titers in patients with esophageal squamous cell carcinoma.
Suzuki T; Yajima S; Ishioka N; Nanami T; Oshima Y; Washizawa N; Funahashi K; Otsuka S; Nemoto T; Shimada H
Esophagus; 2018 Oct; 15(4):294-300. PubMed ID: 29959634
[TBL] [Abstract][Full Text] [Related]
15. The detection of quantitative serum p53 protein in lung cancer.
Sen E; Gönüllü U; Akar N
Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer.
Feng W; Li Y; Shen L; Cai XW; Zhu ZF; Chang JH; Xiang JQ; Zhang YW; Chen HQ; Fu XL
Oncotarget; 2016 Feb; 7(6):7227-40. PubMed ID: 26811495
[TBL] [Abstract][Full Text] [Related]
17. Receptor for hyaluronic acid-mediated motility (RHAMM, CD168) expression is prognostically important in both nodal negative and nodal positive large cell lung cancer.
Augustin F; Fiegl M; Schmid T; Pomme G; Sterlacci W; Tzankov A
J Clin Pathol; 2015 May; 68(5):368-73. PubMed ID: 25731190
[TBL] [Abstract][Full Text] [Related]
18. Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients.
Yu DH; Li JH; Wang YC; Xu JG; Pan PT; Wang L
Clin Chim Acta; 2011 May; 412(11-12):930-5. PubMed ID: 21277290
[TBL] [Abstract][Full Text] [Related]
19. Serum anti-p53 antibodies in patients with lung cancer.
Mack U; Ukena D; Montenarh M; Sybrecht GW
Oncol Rep; 2000; 7(3):669-74. PubMed ID: 10767388
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of number of resected and involved lymph nodes at complete resection on survival in non-small cell lung cancer.
Saji H; Tsuboi M; Yoshida K; Kato Y; Nomura M; Matsubayashi J; Nagao T; Kakihana M; Usuda J; Kajiwara N; Ohira T; Ikeda N
J Thorac Oncol; 2011 Nov; 6(11):1865-71. PubMed ID: 21964529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
